Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Aslan Pharmaceuticals Pte Ltd has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners but are contained within 1 distinct art unit. This concentration in a single art unit suggests a focused examination environment despite the involvement of 2 distinct examiners reviewing the applications.
The busiest examiner, VALENROD, YEVGENY, is responsible for 1 pending office action. This represents 1 of the 2 total pending office actions currently facing the company. With the workload split among the assigned examiners within the identified Biotechnology & Pharmaceuticals unit, this examiner's role is central to the company's current interactions with the 1 distinct art unit.
Practitioners should observe that while the pending office actions are handled by different individuals, the shared art unit may lead to consistent subject matter expertise being applied to the Biotechnology & Pharmaceuticals filings. VALENROD, YEVGENY, with 1 pending office action, is a key figure in this portfolio. The art unit serves as the primary administrative hub for these matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
| WEDDINGTON, KEVIN E | 1 | 75.2% | +9.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18184657 | TREATMENT OF AUTOIMMUNE SKIN DISEASE | WEDDINGTON, KEVIN E | 182d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18835823 | DHODH INHIBITOR POLYMORPH | VALENROD, YEVGENY | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18835823 | DHODH INHIBITOR POLYMORPH | VALENROD, YEVGENY | — | §112 | Non-Final OA | — | Pending | Aug 05, 2024 |
| 18184657 | TREATMENT OF AUTOIMMUNE SKIN DISEASE | WEDDINGTON, KEVIN E | 1629 | §101§102§103§112 | Non-Final OA | 182d overdue | Pending | Mar 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial